TXNIP and metabolic dysfunction-associated steatotic liver disease: For example, Park et al. [53] established a positive correlation between increased TXNIP expression and elevated MAP1LC3B puncta and P62 expression in human nonalcoholic fatty liver disease, providing clinical evidence of the relationship between TXNIP upregulation and autophagy impairment.